B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues.
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
To explore the pathogenesis of chronic lymphocytic leukemia (CLL), we examined whether phosphorylation of one or more signal transducer and activator of transcription (STAT) factors was abnormal in cells from CLL patients. No constitutive tyrosine phosphorylation was detected on any STAT in CLL cells. To assess the phosphorylation of serine residues of STAT1 and STAT3 in CLL cells, we raised antibodies that specifically recognize the form of STAT1 phosphorylated on ser-727 and the form of STAT3 phosphorylated on ser-727. We found that in 100% of patients with CLL (n = 32), STAT1 and STAT3 were constitutively phosphorylated on serine. This was in contrast to normal peripheral blood B lymphocytes or CD5+) B cells isolated from tonsils, in which this phosphorylation was absent. Serine phosphorylation of STAT1 and STAT3 was seen occasionally in other leukemias, but it was a universal finding only in CLL. The serine phosphorylation of these STATs was a continuous process, as incubation of CLL cells with the kinase inhibitor H7 led to the dephosphorylation of these serine residues. The STAT serine kinase in CLL cells has not been identified, and appears to be neither mitogen-activated protein kinase nor pp70(s6k). In summary, the constitutive serine phosphorylation of STAT1 and STAT3 is present in all CLL samples tested to date, although the physiologic significance of this modification remains to be determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylated CREB binds specifically to the nuclear protein CBP
Chrivia, J. C., Kwok, R. P. S., Lamb, N., Hagiwara, M., Montminy, M. R., & Goodman, R. H. (1993) · Nature · doi:10.1038/365855a0 · Cited by 2,052 · cited 1×
“The phosphorylation of ser-133 of the transcription factor CREB (for cAMP response element–binding protein) allows CREB to interact with CREB-binding protein, which appears to be critical for the initiation of transcription (31, 32).”
BackgroundWen, Z., Zhong, Z., & Darnell, J. E. (1995) · Cell · doi:10.1016/0092-8674(95)90311-9 · Cited by 1,974
TRANSCRIPTIONAL RESPONSES TO POLYPEPTIDE LIGANDS: The JAK-STAT Pathway
Schindler, C., & Darnell, J. E. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.003201 · Cited by 1,808
Nuclear protein CBP is a coactivator for the transcription factor CREB
Kwok, R. P. S., Lundblad, J. R., Chrivia, J. C., Richards, J. P., Bächinger, H. P., Brennan, R. G., Roberts, S. G. E., Green, M. R., & Goodman, R. H. (1994) · Nature · doi:10.1038/370223a0 · Cited by 1,443
Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I
Migone, T.-S., Lin, J.-X., Cereseto, A., Mulloy, J. C., O'Shea, J. J., Franchini, G., & Leonard, W. J. (1995) · Science · doi:10.1126/science.7604283 · Cited by 557
Cited by
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743
“In addition, elevated serine kinase activity is associated with oncogenesis (Frank, 1999), and increased levels of serine phosphorylation of Stat1 and Stat3 have been detected in chronic lymphocytic leukemia (CLL) (Frank et al., 1997).”
BackgroundThe molecular details of cytokine signaling via the JAK/STAT pathway
Morris, R., Kershaw, N. J., & Babon, J. J. (2018) · Protein Science · doi:10.1002/pro.3519 · Cited by 943
Marotta, L. L. C., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S. R., Bloushtain-Qimron, N., Kim, J. J., Choudhury, S. A., Maruyama, R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44745 · Cited by 911
Self-citationSerine phosphorylation of STATs
Decker, T., & Kovarik, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203481 · Cited by 887
Suppressors of cytokine signalling (SOCS) in the immune system
Alexander, W. S. (2002) · Nature Reviews Immunology · doi:10.1038/nri818 · Cited by 645
STAT proteins: novel molecular targets for cancer drug discovery
Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1204086 · Cited by 643
Biology and significance of the JAK/STAT signalling pathways
Kiu, H., & Nicholson, S. E. (2012) · Growth Factors · doi:10.3109/08977194.2012.660936 · Cited by 470
“SHP2 has been shown to prevent JAK1 (You et al. 1999), STAT5a (Chen et al. 2003) and STAT1 phosphorylation (the latter at both tyrosine and serine residues) (Wu et al. 2002).”
InfluentialBhunia, A. K., Piontek, K., Boletta, A., Liu, L., Qian, F., Xu, P.-N., Germino, F. J., & Germino, G. G. (2002) · Cell · doi:10.1016/s0092-8674(02)00716-x · Cited by 454
Inflammation and cancer: how friendly is the relationship for cancer patients?
Aggarwal, B. B., & Gehlot, P. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.06.020 · Cited by 405
AGGARWAL, B. B., SETHI, G., AHN, K. S., SANDUR, S. K., PANDEY, M. K., KUNNUMAKKARA, A. B., SUNG, B., & ICHIKAWA, H. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1378.063 · Cited by 398
Perturbation of the normal immune system in patients with CLL
Forconi, F., & Moss, P. (2015) · Blood · doi:10.1182/blood-2015-03-567388 · Cited by 385
B Cell Chronic Lymphocytic Leukemia: Lessons Learned from Studies of the B Cell Antigen Receptor
Chiorazzi, N., & Ferrarini, M. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141018 · Cited by 377
STAT3 as a central mediator of neoplastic cellular transformation
Frank, D. A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.10.017 · Cited by 364
Self-citationStructure, function, and regulation of STAT proteins
Lim, C. P., & Cao, X. (2006) · Molecular BioSystems · doi:10.1039/b606246f · Cited by 354
Damle, R. N. (2002) · Blood · doi:10.1182/blood.v99.11.4087 · Cited by 341
Signal transducer and activator of transcription proteins in leukemias
Benekli, M., Baer, M. R., Baumann, H., & Wetzler, M. (2003) · Blood · doi:10.1182/blood-2002-04-1204 · Cited by 325
Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314
“, 2019) and chronic lymphocytic leukemia (CLL) (Frank et al., 1997; Hazan-Halevy et al., 2010; Lupardus et al., 2014; Antosz et al., 2015; Rozovski et al., 2016, 2017a,b; Kondo et al., 2018).”
BackgroundInfluentialStat5 Is Essential for the Myelo- and Lymphoproliferative Disease Induced by TEL/JAK2
Schwaller, J., Parganas, E., Wang, D., Cain, D., Aster, J. C., Williams, I. R., Lee, C.-K., Gerthner, R., Kitamura, T., Frantsve, J., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00067-8 · Cited by 303
Burger, M., Hartmann, T., Krome, M., Rawluk, J., Tamamura, H., Fujii, N., Kipps, T. J., & Burger, J. A. (2005) · Blood · doi:10.1182/blood-2004-12-4918 · Cited by 295
Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention
Xiong, A., Yang, Z., Shen, Y., Zhou, J., & Shen, Q. (2014) · Cancers · doi:10.3390/cancers6020926 · Cited by 283
The Jak-Stat Pathway: Cytokine Signalling from the Receptor to the Nucleus
Heim, M. H. (1999) · Journal of Receptors and Signal Transduction · doi:10.3109/10799899909036638 · Cited by 271
STAT3, stem cells, cancer stem cells and p63
Galoczova, M., Coates, P., & Vojtesek, B. (2018) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-018-0078-0 · Cited by 269
Turkson, J., Bowman, T., Adnane, J., Zhang, Y., Djeu, J. Y., Sekharam, M., Frank, D. A., Holzman, L. B., Wu, J., Sebti, S., et al. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.11.7519 · Cited by 258
Self-citationTing, L.-M., Kim, A. C., Cattamanchi, A., & Ernst, J. D. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.7.3898 · Cited by 257
Serine Phosphorylation and Negative Regulation of Stat3 by JNK
Lim, C. P., & Cao, X. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.31055 · Cited by 225
STAT signaling in the pathogenesis and treatment of leukemias
Lin, T. S., Mahajan, S., & Frank, D. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203486 · Cited by 205
Self-citationAberrant LPL expression, driven by STAT3, mediates free fatty acid metabolism in CLL cells
Rozovski, U., Grgurevic, S., Bueso-Ramos, C., Harris, D. M., Li, P., Liu, Z., Wu, J. Y., Jain, P., Wierda, W., Burger, J., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0412 · Cited by 83
“Serine pSTAT3migrates to the nucleus, binds to DNA, activates transcription, and provides CLL cells with a survival advantage (13, 14).”
BackgroundRozovski, U., Calin, G. A., Setoyama, T., D’Abundo, L., Harris, D. M., Li, P., Liu, Z., Grgurevic, S., Ferrajoli, A., Faderl, S., et al. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-50 · Cited by 55
“However, in almost all patients, regardless of their cytogenetic abnormalities, clinical characteristics, disease stage, or treatment status, signal transducer and activator of transcription 3 (STAT3) is constitutively phosphorylated on serine 727 residue [3,4].”
BackgroundSingle cell profiling of phospho-protein levels in chronic lymphocytic leukemia
Myhrvold, I. K., Cremaschi, A., Hermansen, J. U., Tjønnfjord, G. E., Munthe, L. A., Taskén, K., & Skånland, S. S. (2018) · Oncotarget · doi:10.18632/oncotarget.23949 · Cited by 30
Metadata
- Authors
- Frank, D. A., Mahajan, S., & Ritz, J.
- Venue
- Journal of Clinical Investigation
- Published
- 1997-12-15
- Volume
- 100
- Issue
- 12
- Pages
- 3140-3148
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2013691481
- Cited by
- 239
- References
- 5
- FWCI
- 9.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.